Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

BACKGROUND: Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized that imat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Reilley, Matthew J., Bailey, Ann, Subbiah, Vivek, Janku, Filip, Naing, Aung, Falchook, Gerald, Karp, Daniel, Piha-Paul, Sarina, Tsimberidou, Apostolia, Fu, Siqing, Lim, JoAnn, Bean, Stacie, Bass, Allison, Montez, Sandra, Vence, Luis, Sharma, Padmanee, Allison, James, Meric-Bernstam, Funda, Hong, David S.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5394629/
https://ncbi.nlm.nih.gov/pubmed/28428884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0238-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki